High Costs Limit Access to Cancer Medications
New study finds that frequent insurance rejections and high out-of-pocket costs drive prescription abandonment.
Updated on Oct. 29, 2026 in Cancer
Live Poll
Do you feel that rising out-of-pocket drug costs prevent you from accessing necessary medical treatments?
A study published on September 30, 2026, reveals that insurance barriers and rising expenses significantly prevent patients from obtaining oral anticancer drugs. Researchers found that over 60% of Medicare and 80% of commercially insured prescriptions faced initial rejection, stalling essential treatment.
Why it matters
Prescription abandonment for blood cancer patients surges when out-of-pocket costs rise or administrative hurdles like prior authorization are imposed. These delays create dangerous gaps in care that can negatively impact patient health outcomes.
Researchers analyzed 12,134 prescriptions, finding that prior authorization requirements accounted for 32.1% of Medicare rejections and 27.8% of commercial rejections. Only 48.5% of commercial prescriptions initially rejected as off-formulary were eventually approved.
The players
Journal of Clinical Oncology
This peer-reviewed medical journal publishes significant research regarding the diagnosis and treatment of cancer.
The details
Investigators reviewed 2022 pharmacy and medical claims to track how insurance denials and cost thresholds influence patient behavior. The data demonstrates a clear correlation between increased costs and decreased fulfillment, as Medicare patient fill rates dropped from 76.7% to 38.0% when costs exceeded $175.
Timeline
2018: An earlier study regarding out-of-pocket costs and abandonment was published.
2022: Researchers analyzed 12,134 patient prescriptions from this year.
September 30, 2026: The study was published in the Journal of Clinical Oncology.
2026: Medicare Part D implemented an annual out-of-pocket spending cap of $2,100.
Health Landscape
This study reflects the broader trend of insurance-driven barriers to care that contradict the intent of the Inflation Reduction Act's Medicare drug-price negotiation provisions. These findings demonstrate how administrative hurdles continue to undermine policy efforts to reduce financial toxicity for cancer patients.
Patients facing high costs for blood cancer treatments may find relief through the 2026 Medicare Part D out-of-pocket cap of $2,100. Those struggling with formulary rejections should consult their provider about available payment plans and authorization appeals.
The takeaway
Patients should actively work with their oncology care teams to appeal denials, as nearly half of initial off-formulary rejections for commercial plans were reversed. Understanding your specific insurance formulary and the annual out-of-pocket caps can help manage treatment expenses.
Further reading
Find more updates on current standards of care in our Cancer section.
More information
Review available resources and eligibility details via the Medicare prescription payment plan information.
Source note: This article includes information reported by Pharmacytimes.
Live Poll
Do you feel that rising out-of-pocket drug costs prevent you from accessing necessary medical treatments?
